Akamine, M.A.V.; Ferreira Soares, B.M.A.; Telles, J.P.M.; Cicupira Rodrigues de Assis, A.; Rodriguez, G.N.V.; Soares, P.R.; Chalela, W.A.; Scudeler, T.L.
Role of Dapagliflozin in Ischemic Preconditioning in Patients with Symptomatic Coronary Artery Disease—DAPA-IP Study Protocol. Pharmaceuticals 2024, 17, 920.
https://doi.org/10.3390/ph17070920
AMA Style
Akamine MAV, Ferreira Soares BMA, Telles JPM, Cicupira Rodrigues de Assis A, Rodriguez GNV, Soares PR, Chalela WA, Scudeler TL.
Role of Dapagliflozin in Ischemic Preconditioning in Patients with Symptomatic Coronary Artery Disease—DAPA-IP Study Protocol. Pharmaceuticals. 2024; 17(7):920.
https://doi.org/10.3390/ph17070920
Chicago/Turabian Style
Akamine, Marco Alexander Valverde, Beatriz Moreira Ayub Ferreira Soares, João Paulo Mota Telles, Arthur Cicupira Rodrigues de Assis, Gabriela Nicole Valverde Rodriguez, Paulo Rogério Soares, William Azem Chalela, and Thiago Luis Scudeler.
2024. "Role of Dapagliflozin in Ischemic Preconditioning in Patients with Symptomatic Coronary Artery Disease—DAPA-IP Study Protocol" Pharmaceuticals 17, no. 7: 920.
https://doi.org/10.3390/ph17070920
APA Style
Akamine, M. A. V., Ferreira Soares, B. M. A., Telles, J. P. M., Cicupira Rodrigues de Assis, A., Rodriguez, G. N. V., Soares, P. R., Chalela, W. A., & Scudeler, T. L.
(2024). Role of Dapagliflozin in Ischemic Preconditioning in Patients with Symptomatic Coronary Artery Disease—DAPA-IP Study Protocol. Pharmaceuticals, 17(7), 920.
https://doi.org/10.3390/ph17070920
